Cliquez sur les images pour acquérir mes livres : frais de port gratuits et envoi rapide.

Pour suivre mon actualité ou me contacter : sur Facebook.

Le mystère des aliments riche en mélatonine

31/12/2016 | Etudes sur les hormones et Etudes Compléments alimentaires et Etudes Anti-âge


Are the proposed benefits of melatonin-rich foods too hard to swallow?
David J. Kennaway     Critical Reviews in Food Science and Nutrition   2016 Pages 958-962

Melatonin has been proposed as a potent anti-oxidant, and its presence in many plants and foods has been suggested to be beneficial for health. Indeed, the concentrations of melatonin in blood and the melatonin metabolite 6 sulphatoxymelatonin in urine have been found to increase significantly after ingestion of melatonin-rich foods. In this review, the studies have been critically evaluated in light of the reported plant melatonin concentrations and our knowledge of pharmacokinetics of orally administered pure melatonin. In the case of studies involving measurement of plasma melatonin following ingestion of beer or fruits, the reported increase in melatonin is not consistent with the amount of melatonin ingested. Similarly, the amount of melatonin metabolite excreted following ingestion of melatonin-rich foods greatly exceeded the amount of melatonin ingested.

It is concluded that studies reporting the appearance of melatonin in blood and its metabolites in urine following ingestion of melatonin-rich foods are flawed. While there may be health benefits for certain foods, it is difficult to accept that these are due to their low melatonin content.


Une blessure peut avoir des conséquences psychologiques graves

08/12/2016 | Echauffement et blessures


Are severe musculoskeletal injuries associated with symptoms of common mental disorders among male European professional footballers?
Knee Surgery, Sports Traumatology, Arthroscopy December 2016, Volume 24, Issue 12, pp 3934–3942   Vincent Gouttebarge


To explore the associations of severe musculoskeletal injuries (joint and muscles) and surgeries with symptoms of common mental disorders (distress, anxiety/depression, sleeping disturbance, adverse alcohol behaviour , smoking, adverse nutrition behaviour) among male European professional footballers.


Cross-sectional analyses were conducted on electronic questionnaires completed by professional footballers recruited from the national players’ unions of Finland, France, Norway, Spain or Sweden. The number of severe (time loss of more than 28 days) musculoskeletal injuries (total, joint, muscle) and surgeries during a professional football career was examined through four questions, while symptoms of common mental disorders were evaluated through validated scales.


A total of 540 professional footballers (mean age of 27 years; 54 % playing in the highest leagues) participated in the study. Sixty-eight per cent of the participants had already incurred one or more severe joint injuries and 60 % one or more severe muscle injuries. Prevalence of symptoms of common mental disorders ranged from 3 % for smoking to 37 % for anxiety/depression and 58 % for adverse nutrition behaviour. The number of severe musculoskeletal injuries during a football career was positively correlated with distress, anxiety and sleeping disturbance, while the number of surgeries was correlated with adverse alcohol behaviour and smoking. Professional footballers who had sustained one or more severe musculoskeletal injuries during their career were two to nearly four times more likely to report symptoms of common mental disorders than professional footballers who had not suffered from severe musculoskeletal injuries.


It can be concluded that the number of severe musculoskeletal injuries and surgeries during a career is positively correlated and associated with symptoms of common mental disorders among male European professional footballers. This study emphasises the importance of applying a multidisciplinary approach to the clinical care and support of professional footballers, especially when a player faces lengthy periods without training and competition as a consequence of recurrent severe joint or muscle injuries.

Le Viagra est-il aussi un anti-aromatase?

01/12/2016 | Etudes Perte de poids et Etudes Anti-âge et Etudes sur les boosters sexuels et la sexualité


Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells
The Journal of Steroid Biochemistry and Molecular Biology Volume 165, Part B, January 2017, Pages 438–447       Roberta Baravalle

• Human aromatase binds the drug sildenafil showing a Type II spectrum.
• EPR spectroscopy shows that sildenafil does not directly bind heme iron.
• Sildenafil acts as a mixed and partial inhibitor on human aromatase.
• Aromatase inhibition by sildenafil is confirmed in ST14A and MCF-7 cells.

Aromatase catalyses the conversion of androgens into estrogens and is a well-known target for breast cancer therapy. As it has been suggested that its activity is affected by inhibitors of phosphodiesterase-5, this work investigates the potential interaction of sildenafil with aromatase. This is carried out both at molecular level through structural and kinetics assays applied to the purified enzyme, and at cellular level using neuronal and breast cancer cell lines.

Sildenafil is found to bind to aromatase with a KD of 0.58 ± 0.05 μM acting as a partial and mixed inhibitor with a maximal inhibition of 35 ± 2%. Hyperfine sublevel correlation spectroscopy and docking studies show that sildenafil binds to the heme iron via its 6th axial water ligand.

These results also provide information on the starting molecular scaffold for the development of new generations of drugs designed to inhibit aromatase as well as phosphodiesterase-5, a new emerging target for breast cancer therapy.

Le curcuma est-il un inhibiteur de la 5 alpha réductase?

27/11/2016 | Etudes Compléments alimentaires et Etudes Anti-âge et Etudes sur les boosters sexuels et la sexualité


A new label-free screen for steroid 5α-reductase inhibitors using LC-MS
Steroids Volume 116, December 2016, Pages 67–75       Jukkarin Srivilai

• A novel assay for 5 alpha reductase (S5αR) activity determination based on LC-MS quantitation of DHT.
• The assay showed high reproducibility and selectivity with Z′ factor of 0.77.
• The method was successfully used to quantify S5αR inhibitory activity of some herbal extracts.

Steroid 5α-reductase (S5αR) plays an important role in metabolizing testosterone into active androgen dihydrotestosterone (DHT) which is involved in many androgen dependent disorders, such as androgenic alopecia, benign prostatic hyperplasia and acne. The method for screening for S5αR inhibition is key in finding new antagonists. In this study, the label-free S5αR inhibitory assay using LC-MS was developed. S5αR type 1 enzyme was obtained from LNCaP prostate cancer cells. The enzymatic assay was optimised for enzyme-substrate (testosterone) concentration, NADPH-cofactor concentration, solvent tolerance, enzyme activity stability and incubation time. The developed assay was validated by measuring the signal to background ratio (S/B), the signal to noise ratio (S/N), the signal window (SW) and the zeta factor Z′ in accordance with published bioassay guidelines. The enzymatic reaction was performed in 96-well plates and DHT formation was determined by LC-MS. S/B, S/N, SW and Z′ factor were well above acceptable criteria and the reproducibility was good using Z′ factor other 3 days and further validated by dutasteride and finasteride inhibition. The method was successfully applied to quantify S5αR inhibitory activity of some Thai herbal extracts.

Two plant extracts, Impatiens balsamina L. and Curcuma longa L. showed IC50 at 5.4 ± 0.2 and 9.0 ± 1.2 μg mL−1 and are therefore promising sources of new S5αR inhibitors. The assay has high selectability and reproducibility and suited to medium throughput screening required by phytochemistry.

Quels impacts des corps cétoniques chez le sportif?

18/11/2016 | Etudes Compléments alimentaires et Etudes Perte de poids


Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation
Mark Evans                   J Physiol 2016

Optimising training and performance through nutrition strategies is central to supporting elite sportspeople, much of which has focussed on manipulating the relative intake of carbohydrate and fat and their contributions as fuels for energy provision. The ketone bodies, namely acetoacetate, acetone, and β-hydroxybutyrate (βHB), are produced in the liver during conditions of reduced carbohydrate availability and serve as an alternative fuel source for peripheral tissues including brain, heart and skeletal muscle.

Ketone bodies are oxidised as a fuel source during exercise, are markedly elevated during the post-exercise recovery period, and the ability to utilise ketone bodies is higher in exercise-trained skeletal muscle. The metabolic actions of ketone bodies can alter fuel selection through attenuating glucose utilisation in peripheral tissues, anti-lipolytic effects on adipose tissue, and attenuation of proteolysis in skeletal muscle. Moreover, ketone bodies can act as signalling metabolites with βHB acting as an inhibitor of histone deacetylases, an important regulator of the adaptive response to exercise in skeletal muscle.

Recent development of ketone esters facilitates acute ingestion of βHB that results in nutritional ketosis without necessitating restrictive dietary practices. Initial reports suggest this strategy alters the metabolic response to exercise and improves exercise performance, while other lines of evidence suggest roles in recovery from exercise.

The present review focuses on the physiology of ketone bodies during and after exercise and in response to training, with specific interest in exploring the physiological basis for exogenous ketone supplementation and potential benefits for performance and recovery in athletes.

Effets de l’exercice sur les concentrations de l’irisine

21/10/2016 | Etudes cardio et Etudes Musculation et Etudes Perte de poids et Etudes Anti-âge


Effets de l’exercice sur les concentrations de l’irisine circulatoire chez les adultes sains : revue générale
Science & Sports Volume 31, Issue 5, October 2016, Pages 251–260       A.C. Rodrigues


L’irisine est une myokine induite par l’exercice, responsable de la régulation de la protéine découplante 1 (UCP-1) dans le tissu adipeux beige. Cette étude vise à faire le point sur les effets d’exercice aigus et chroniques sur les concentrations circulantes d’irisine chez les adultes sains.


Nous avons réalisé, à partir des bases de données Medline et ScienceDirect, une revue de la littérature parue entre janvier 2012 et mars 2016, en utilisant les termes d’indexation suivants : irisine, exercice aigu, exercice chronique et entraînement. Pour les besoins de l’analyse, les études ont été divisés en exercice aigu et exercice chronique. Seize articles répondaient aux critères d’inclusion/exclusion, huit études portant sur l’exercice aigu, quatre avec l’exercice chronique et quatre avec les deux. Parmi les études portant sur l’exercice aigu, deux seulement n’ont pas observé d’augmentation des concentrations sériques et plasmatiques d’irisine après la séance d’exercice. L’exercice en résistance et l’exercice à haute intensité augmentaient davantage l’irisine que l’exercice aérobie et que l’exercice à faible d’intensité. Une seule étude a révélé une augmentation des concentrations circulantes d’irisine après plusieurs semaines d’entraînement en comparaison aux concentrations mesurées avant entraînement. Une autre étude a observé une augmentation des concentrations circulantes d’irisine dans le groupe entraîné par rapport au groupe témoin.


L’exercice aigu augmente les concentrations circulantes d’irisine. L’exercice en résistance et l’exercice à haute intensité augmentent davantage l’irisine. Par contre, un entraînement prolongé de plusieurs semaines ne semble pas modifier les concentrations circulantes d’irisine.

Urolithine B comme un nouveau régulateur de la masse musculaire

19/10/2016 | Etudes Compléments alimentaires et Etudes Perte de poids et Etudes Anti-âge


Identification de l’urolithine B comme un nouveau régulateur de la masse musculaire
Nutrition Clinique et Métabolisme Volume 30, Issue 3, September 2016, Pages 252         J. Rodriguez

Introduction et but de l’étude
Le muscle squelettique est le tissu le plus abondant du corps humain. Le contrôle de sa masse est essentiel pour assurer ses fonctions physiologiques comme la locomotion, la respiration ou encore la posture. Il joue également un rôle majeur dans le contrôle du métabolisme. L’atrophie musculaire est associée à une diminution de force, à des désordres métaboliques et à une mauvaise qualité de vie. Par conséquent, les stratégies nutritionnelles visant à atténuer la fonte musculaire liée à des conditions (patho) physiologiques représentent un intérêt thérapeutique majeur. Le but de cette étude est d’évaluer les effets de l’urolitine B, un métabolite des éllagitanins, sur le croissance et la fonte musculaire.

Matériel et méthodes
Des myotubes C2C12 ont été incubés 24 h en présence de 15 μM d’urolithine B. La croissance cellulaire, la synthèse et la dégradation protéiques ont été mesurées et les voies de signalisation associées ont été systématiquement étudiées. Afin d’évaluer in vivo les effets sur l’hypertrophie, des minipompes osmotiques délivrant de manière continue 10 μg d’urolithine B par jour pendant 28 jours ont été implantées à des souris. Les effets sur l’atrophie ont été étudiés après section du nerf sciatique et implantation de minipompes osmotiques (10 μg d’urolithine B, par jour, durant 3 ou 7 jours).

Résultats et analyse statistique
L’urolithine B stimule la croissance des myotubes (+ 40 %, p < 0,001), augmente la synthèse (+ 90 %, p < 0,001) et diminue la dégradation protéique (− 20 %, p < 0,001). L’analyse des voies de signalisation révèle une plus grande activité de la voie de mTORC1 et une inhibition du système ubiquitine–protéasome. Le récepteur aux androgènes semble impliqué puisque son inhibition par un siRNA ou un agent pharmacologique bloque totalement l’hypertrophie induite par l’urolithine B. Cette dernière stimule la croissance musculaire chez la souris en augmentant la synthèse des protéines (activité trois fois supérieure dans le muscle tibialis anterior) et réduit l’atrophie induite par une dénervation.

Nos résultats indiquent que l’urolithine B régule la masse musculaire probablement en agissant via le récepteur aux androgènes. Notre étude met ainsi en évidence l’utilité potentielle de l’urolithine B dans le traitement de l’atrophie musculaire observée dans plusieurs situations patho-physiologiques.

Page 1 sur 187 pages  1 2 3 >  Last »